Cormorant Asset Management, LP Prometheus Biosciences, Inc. Transaction History

Cormorant Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $45 Million - $54.9 Million	-435,000 Reduced 20.81%	1,655,000 $178 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $4 Million - $13 Million	110,842 Added 5.6%	2,090,000 $230 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $1.41 Million - $2.95 Million	-50,000 Reduced 2.46%	1,979,158 $117 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $4.61 Million - $8.01 Million	205,714 Added 11.28%	2,029,158 $57.3 Million
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $740,595 - $1.23 Million	-24,580 Reduced 1.33%	1,823,444 $68.9 Million
Q2 2021 Aug 16, 2021	SELL	$16.8 - $29.65 $4.2 Million - $7.41 Million	-250,000 Reduced 11.92%	1,848,024 $44.5 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $34.6 Million - $53.1 Million	2,098,024 New	2,098,024 $36.6 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.